文献速递妇科

新辅助化疗与晚期卵巢癌患者更多贫血及围手术期输血相关:对比初次肿瘤细胞减灭术

Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2018-01-01

本单中心病例对照研究纳入2010至2013年IIIB-IVB期上皮性卵巢癌患者131例,66例接受新辅助化疗(NACT),65例接受初次肿瘤细胞减灭术(PDS)。NACT组术前平均血红蛋白更低(10.7 g/dL vs 12.8 g/dL,p<0.0001),术前贫血比例更高(77% vs 15%,p<0.001),围手术期输血率更高(77% vs 56%,p=0.01),尽管减灭术估计失血量更少(544 mL vs 871 mL)。

要点

  • NACT组术前平均血红蛋白10.7 g/dL,低于PDS组的12.8 g/dL(p<0.0001)。
  • NACT组术前贫血比例77%,高于PDS组的15%(p<0.001)。
  • NACT组围手术期输血率77%,高于PDS组的56%(p=0.01)。

核心结论

  • 选择NACT的女性在诊断时更可能贫血,并在NACT期间贫血进行性加重。
  • 尽管减灭手术失血更少,NACT患者围手术期输血多于PDS患者。
  • 这为NACT期间治疗干预以在间歇性减灭术前纠正贫血提供了潜在机会。

研究设计与样本

  • 单中心病例对照研究,回顾2010至2013年诊断为IIIB-IVB期上皮性卵巢癌并接受NACT或PDS的患者。
  • 共纳入131例女性,66例接受NACT,65例接受PDS。
  • 贫血定义为血红蛋白浓度≤11.5 g/dL。
  • 连续变量采用学生t检验比较,二分类变量采用卡方分析比较。

主要发现

  • NACT组术前平均血红蛋白10.7 g/dL,PDS组12.8 g/dL(p<0.0001)。
  • NACT组化疗期间平均血红蛋白从诊断时11.8 g/dL降至术前10.7 g/dL。
  • NACT组术前贫血77%,PDS组术前贫血15%(p<0.001)。
  • 减灭术平均估计失血量PDS组871 mL,NACT组544 mL。
  • 围手术期输血率NACT组77%,PDS组56%(p=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this case-controlled study was to determine the prevalence of anemia and incidence of perioperative blood transfusions in patients undergoing treatment for advanced ovarian cancer with neoadjuvant chemotherapy (NACT) or primary debulking surgery (PDS). METHODS: We performed a single institution review of patients diagnosed with stage IIIB-IVB epithelial ovarian cancer between 2010 and 2013 undergoing either NACT or PDS. Anemia was defined as a hemoglobin (Hgb) concentration of ≤11.5 g/dL. Continuous variables were compared by student t-test and binary variables compared via chi square analysis. RESULTS: One hundred thirty-one women were included, 66 treated with NACT and 65 treated with PDS. Average Hgb prior to surgery was lower in women who received NACT (10.7 g/dL vs 12.8 g/dL, p < 0.0001). Women treated with NACT had a decrease in mean Hgb during chemotherapy treatment (11.8 g/dL at diagnosis to 10.7 g/dL preoperatively). Seventy-seven percent of NACT patients were anemic prior to surgery compared to 15% of patients prior to PDS (p < 0.001). Mean EBL at debulking was higher in patients selected for PDS (871 mL) than NACT (544 mL); however, the perioperative transfusion rate was higher during interval debulking surgeries (NACT 77% vs PDS 56%, p = 0.01). CONCLUSION: Women selected for NACT were more likely to be anemic at diagnosis and became progressively anemic during NACT. Despite less blood loss during debulking surgery, NACT patients receive more blood transfusions perioperatively than patients undergoing PDS. This represents a potential opportunity for therapeutic intervention during NACT to correct anemia prior to interval debulking surgery.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. O'Shea A, McCool K, Harrison R, et al. Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer. Gynecol Oncol. 2018. PMID: 29773300. doi:10.1016/j.ygyno.2018.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。